Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

TNF Inhibitors Associated with Neurological Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2022

A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.

Filed under:ConditionsDrug Updates Tagged with:adverse eventsbrainEULARneurological demyelinating adverse eventsTNF inhibitorstumor necrosis factor (TNF) inhibitors

The 2022 ARP President’s & Merit Awards

Patrice Fusillo  |  November 6, 2022

During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

Filed under:AwardsProfessional TopicsResearch Rheum Tagged with:Adena BattermanBrit DonaldsonClinical researchDr. Aileen DavisDr. Charles G. HelmickDr. Jan K. RichardsonDr. Janet L. PooleDr. Kaleb MichaudDr. Linda LiHannah PetersonHeather BenhamMarian T. HannanSue MacQueenThomas Bye

Speak Out Rheum: Racism’s Impact on Patient-Provider Relationships

Mia Taylor Chandler, MD, MPH  |  November 6, 2022

“I tell everyone who comes into her room now, ‘You will not disrespect my daughter again. No one will,’” recounts Sarah’s mother. “Every time a [provider] acts rude to her, Sarah tells me, ‘Ma, I’m used to it now,’ and I have to insist ‘No! Baby, you should never get used to that.’ … Dr….

Filed under:OpinionProfessional TopicsSpeak Out Rheum Tagged with:biasDisparitiesRacismSpeak Out Rheumatology

Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

Richard Brasington Jr., MD, FACP, MACR  |  November 4, 2022

I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

Filed under:AnalgesicsDrug UpdatesOpinionSpeak Out Rheum Tagged with:opioid crisisPain Syndrome FocusRheumSpeak Out Rheumatology

ajt/shutterstock.com

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2022

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

Filed under:Axial SpondyloarthritisConditionsDrug Updates Tagged with:AS Resource CenterJAK inhibitorsnon-radiographic axial spondyloarthritisnr-axSpAspondyloarthritisupadacitinib

ACR Honors Distinguished Fellows at ACR Convergence 2022

Patrice Fusillo  |  October 21, 2022

Editor’s note: This has been extended from the print version to include additional background information on each recipient. Each year, the ACR honors up to 10 clinical and research fellows who have performed meritoriously. Meet this year’s Distinguished Fellows, who are bridging the gap between research and patient care, and who were recognized at ACR…

Filed under:AwardsFrom the CollegeProfessional Topics Tagged with:Dr. Ahmad RamahiDr. Ajay TambralliDr. D. Sofia Villacis NunezDr. Didem SayginDr. Elizabeth ParkDr. Fatima AlduraibiDr. Melanie H. SmithDr. Michael LoncharichDr. Rachel WallworkDr. Rebecca B. BlankFellows

Changing Treatment Patterns for Patients with JIA

Lara C. Pullen, PhD  |  October 18, 2022

A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.

Filed under:ConditionsPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:ChildrenILARJIAjuvenile idiopathic arthritis (JIA)Pediatric

Clinical Academic Rheumatology Generates Profits for Health Systems

Lara C. Pullen, PhD  |  October 11, 2022

Rheumatologists should be better compensated, in part, due to the revenue they bring to the hospital system from their procedures, argue D’Anna et al., who found that clinical academic rheumatologists bring significant downstream revenue to the healthcare system.

Filed under:Career DevelopmentProfessional Topics Tagged with:AcademiaAcademicHealth caremoneyrheumatologists

Lessons from Master Clinicians: An Interview with Dr. Gary Hoffman

Jason Liebowitz, MD, FACR  |  October 10, 2022

Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Gary Hoffman, MD, MS, MACR,…

Filed under:Profiles Tagged with:Dr. Gary HoffmanLessons from Master CliniciansRole Models in Rheumatology

A Case of Nodular Rash & Painful Joints

Vania Lin, MD, MPH, Rebecca Johnson, MD, & Lisa Suter, MD  |  October 10, 2022

Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…

Filed under:ConditionsVasculitis Tagged with:case reportFellowsFellows Forumpolyarteritis nodosa

  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences